The amount of additional milestone payments to be received up on met of secondary end points for the license.

No definition available.

Name:	glpg_AdditionalMilestoneFeeReceivedSecondaryEndPointsAreMetForLicense
Namespace Prefix:	glpg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Arithmetic Mean 30 Day Daily Volume Weighted Average Trading Price of Entity, Multiplier, Exercise Price Per Share

+ References

No definition available.

+ Details

Name:	glpg_ArithmeticMean30DayDailyVolumeWeightedAverageTradingPriceOfEntityMultiplierExercisePricePerShare
Namespace Prefix:	glpg_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

It represents the cost share mechanism for the future development activities, development and sales milestones and royalties.

+ References

No definition available.

+ Details

Name:	glpg_CostShareForGlobalDevelopmentActivities
Namespace Prefix:	glpg_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the development and regulatory milestone payments.

+ References

No definition available.

+ Details

Name:	glpg_DevelopmentAndRegulatoryMilestones
Namespace Prefix:	glpg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The extended period for which sharing of cost if election of option to extend to outside domicile.

+ References

No definition available.

+ Details

Name:	glpg_ExtendedProgramsOptionRightSharingPeriod
Namespace Prefix:	glpg_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The period from which extra ordinary general meeting (EGM) will ne conducted from the close of subscription agreement.

+ References

No definition available.

+ Details

Name:	glpg_ExtraOrdinaryGeneralMeetingConductPeriodFromDateOfClosingOfSubscriptionAgreement
Namespace Prefix:	glpg_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of ratio at which future development cost will be shared before predetermined level.

+ References

No definition available.

+ Details

Name:	glpg_FutureGlobalDevelopmentCostsSharingRatioBeforePredeterminedLevel
Namespace Prefix:	glpg_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The period of contract for global research and collaboration.

+ References

No definition available.

+ Details

Name:	glpg_GlobalResearchAndDevelopmentCollaborationTerm
Namespace Prefix:	glpg_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the initial term of the warrant.

+ References

No definition available.

+ Details

Name:	glpg_InitialWarrantTerm
Namespace Prefix:	glpg_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The maximum percentage of shares can hold up to certain period as per the agreement.

+ References

No definition available.

+ Details

Name:	glpg_MaximumShareHoldingPercentageLimitationForCertainPeriod
Namespace Prefix:	glpg_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of milestone fee to be received if option to license.

+ References

No definition available.

+ Details

Name:	glpg_MilestoneFeeReceivedElectionOfOptionToLicense
Namespace Prefix:	glpg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The number of directors represented or appointed as board of directors.

+ References

No definition available.

+ Details

Name:	glpg_NumberOfDirectorsRepresentedAsBoardOfDirectors
Namespace Prefix:	glpg_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of milestone payments achieved in current period.

+ References

No definition available.

+ Details

Name:	glpg_NumberOfMilestonePaymentsAchievedInCurrentPeriod
Namespace Prefix:	glpg_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of molecules having right to access by the other party due to collaboration agreement.

+ References

No definition available.

+ Details

Name:	glpg_NumberOfMoleculesHavingAccessToOtherParty
Namespace Prefix:	glpg_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of preclinical program having right to access by the other party due to collaboration agreement.

+ References

No definition available.

+ Details

Name:	glpg_NumberOfPreclinicalProgramsHavingAccessToOtherParty
Namespace Prefix:	glpg_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of opt-in payments to be received for each program collaboration opted.

+ References

No definition available.

+ Details

Name:	glpg_OptInPaymentsToBeReceivedForEachProgramCollaborationOpted
Namespace Prefix:	glpg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The period of restrictions of change in ownership interest beyond certain levels.

+ References

No definition available.

+ Details

Name:	glpg_PeriodOfRestrictionOnChangeInOwnershipInterestBeyondCertainLevels
Namespace Prefix:	glpg_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of premium shares was issued to other party.

+ References

No definition available.

+ Details

Name:	glpg_PremiumPercentageOnSharePrice
Namespace Prefix:	glpg_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash inflow from the exercise of warrants.

+ References

No definition available.

+ Details

Name:	glpg_ProceedsFromExerciseOfWarrants
Namespace Prefix:	glpg_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of cash inflow from completion of milestone payments received.

+ References

No definition available.

+ Details

Name:	glpg_ProceedsFromMilestonePayments
Namespace Prefix:	glpg_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The percentage of ratio at which share of profits.

+ References

No definition available.

+ Details

Name:	glpg_ProfitSharingRatio
Namespace Prefix:	glpg_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The period for which sharing of cost if election of option to extend to outside domicile.

+ References

No definition available.

+ Details

Name:	glpg_ProgramsOptionRightSharingPeriod
Namespace Prefix:	glpg_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of regulatory milestone payments received on approval of license.

+ References

No definition available.

+ Details

Name:	glpg_RegulatoryMilestonePaymentsApprovalOfLicense
Namespace Prefix:	glpg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of sales based milestone payments to be received.

+ References

No definition available.

+ Details

Name:	glpg_SalesBasedMilestonePaymentsToBeReceived
Namespace Prefix:	glpg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent summary of significant transaction.

+ References

No definition available.

+ Details

Name:	glpg_SummaryOfSignificantTransactionLineItems
Namespace Prefix:	glpg_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of tiered royalties percentage on sales.

+ References

No definition available.

+ Details

Name:	glpg_TieredRoyaltiesPercentageOnNetSales
Namespace Prefix:	glpg_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of cash inflow received as upfront payment.

+ References

No definition available.

+ Details

Name:	glpg_UpfrontPaymentReceived
Namespace Prefix:	glpg_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The period of volume taken as base for calculation of weighted average share price.

+ References

No definition available.

+ Details

Name:	glpg_WeightedAverageSharePriceCalculatedPeriod
Namespace Prefix:	glpg_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2019-01-01
-Paragraph 24
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_24_a&doctype=Standard
-URIDate 2019-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2019-01-01
-Paragraph B16
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B16&doctype=Appendix&subtype=B
-URIDate 2019-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2019-01-01
-Paragraph 54
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_54_e&doctype=Standard
-URIDate 2019-03-27

+ Details

Name:	ifrs-full_InvestmentAccountedForUsingEquityMethod
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2019-01-01
-Paragraph 17
-Subparagraph b
-Clause iii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_17_b_iii&doctype=Standard
-URIDate 2019-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2019-01-01
-Paragraph 16
-Subparagraph b
-Clause iii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_16_b_iii&doctype=Standard
-URIDate 2019-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2019-01-01
-Paragraph 21
-Subparagraph a
-Clause iv
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_21_a_iv&doctype=Standard
-URIDate 2019-03-27

+ Details

Name:	ifrs-full_ProportionOfOwnershipInterestInAssociate
Namespace Prefix:	ifrs-full_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IFRS
-Number 2
-IssueDate 2019-01-01
-Paragraph 45
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2019-en-r&anchor=para_45&doctype=Standard
-URIDate 2019-03-27

+ Details

Name:	ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
Namespace Prefix:	ifrs-full_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

The weighted average share price. [Refer: Weighted average [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2019-01-01
-Paragraph 45
-Subparagraph c
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2019-en-r&anchor=para_45_c&doctype=Standard
-URIDate 2019-03-27

+ Details

Name:	ifrs-full_WeightedAverageSharePrice2019
Namespace Prefix:	ifrs-full_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	ifrs-full_ProductsAndServicesAxis=glpg_Glpg1690LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=glpg_Glpg1972LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=glpg_FilgotinibDrugLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=glpg_FranceGermanyItalySpainAndUnitedKingdomMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=glpg_BelgiumNetherlandsAndLuxembourgMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=ifrs-full_ForeignCountriesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=glpg_CountriesOutsideOfBelgiumFranceGermanyItalyLuxembourgNetherlandsSpainAndUnitedKingdomMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=glpg_GileadMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ClassesOfShareCapitalAxis=glpg_WarrantaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ClassesOfShareCapitalAxis=glpg_WarrantBMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Summary of significant transaction (Details) € / shares in Units, € in Thousands, $ in Millions								1 Months Ended	12 Months Ended
	Nov. 06, 2019 EUR (€)	Oct. 22, 2019 individual € / shares	Aug. 23, 2019 USD ($)	Aug. 23, 2019 EUR (€)	Jul. 14, 2019 € / shares	Jul. 14, 2019 USD ($) Program item	Jul. 13, 2019	Aug. 31, 2019	Dec. 31, 2019 USD ($) Milestone	Dec. 31, 2019 EUR (€) Milestone € / shares	Dec. 31, 2018 EUR (€) € / shares	Dec. 31, 2017 EUR (€) € / shares	Aug. 23, 2019 EUR (€)
Summary of significant transaction
Global research and development collaboration term						10 years
Number of molecules \| item						6
Number of preclinical programs \| Program						20
Upfront payment received			$ 3,950	€ 3,569,800
Equity investment received			$ 1,100										€ 960,100
Additional equity investment from warrant exercise \| €										€ 17,167	€ 7,657	€ 5,288
Cost Share For Global Development Activities									50.00%	50.00%
Number of directors represented as board members \| individual		2
Option rights period						10 years
Extension option rights period						3 years
Opt-in payments to be received for each program						$ 150
Average exercise price warrants \| € / shares										€ 22.8	€ 13.5	€ 14.4
GLPG 1690 License
Summary of significant transaction
Regulatory milestone fee						325
GLPG 1972 License
Summary of significant transaction
Regulatory milestone fee						550
Additional milestone fee						$ 200
Filgotinib drug license
Summary of significant transaction
Future global development cost sharing ratio before predetermined level						80.00%
Development and regulatory milestones						$ 640
Sales based milestone payment						600
Number of milestone payments achieved \| Milestone									2	2
Proceeds from milestone payments									$ 30
United States \| GLPG 1972 License
Summary of significant transaction
Milestone fee on election of option to license						$ 250
France, Germany, Italy, Spain and the United Kingdom \| Filgotinib drug license
Summary of significant transaction
Profit sharing ratio						50.00%
Belgium, the Netherlands and Luxembourg \| Filgotinib drug license
Summary of significant transaction
Profit sharing ratio						50.00%
Minimum
Summary of significant transaction
Cost Share For Global Development Activities			20.00%										20.00%
Minimum \| Outside Europe
Summary of significant transaction
Tiered royalty Percentage						20.00%
Minimum \| Outside Europe \| GLPG 1690 License
Summary of significant transaction
Tiered royalty Percentage						20.00%
Minimum \| Countries outside of Belgium, France, Germany, Italy, Luxembourg, the Netherlands, Spain and the United Kingdom \| Filgotinib drug license
Summary of significant transaction
Tiered royalty Percentage						20.00%		20.00%
Maximum
Summary of significant transaction
Cost Share For Global Development Activities			50.00%										50.00%
Maximum \| Outside Europe
Summary of significant transaction
Tiered royalty Percentage						24.00%
Maximum \| Outside Europe \| GLPG 1690 License
Summary of significant transaction
Tiered royalty Percentage						24.00%
Maximum \| Countries outside of Belgium, France, Germany, Italy, Luxembourg, the Netherlands, Spain and the United Kingdom \| Filgotinib drug license
Summary of significant transaction
Tiered royalty Percentage						30.00%		30.00%
Gilead
Summary of significant transaction
Share price \| € / shares					€ 140.59
Premium						20.00%
Volume of days						30 days
Percentage of stake	25.10%					22.04%	12.30%		25.84%	25.84%
Restricting Gilead's ability to seek to acquire		10 years
Maximum share holding percentage		29.90%
Gilead \| Filgotinib drug license
Summary of significant transaction
Future global development cost sharing ratio before predetermined level						20.00%
Gilead \| France, Germany, Italy, Spain and the United Kingdom \| Filgotinib drug license
Summary of significant transaction
Profit sharing ratio						50.00%
Gilead \| Belgium, the Netherlands and Luxembourg \| Filgotinib drug license
Summary of significant transaction
Profit sharing ratio						50.00%
Gilead \| Minimum
Summary of significant transaction
EGM Conducted period		57 months
Gilead \| Maximum
Summary of significant transaction
Percentage of stake		29.90%
EGM Conducted period		59 months
Warrant A \| Gilead
Summary of significant transaction
Additional equity investment from warrant exercise \| €	€ 368,000
Warrant B
Summary of significant transaction
Multiplier used to calculate exercise price per share		120.00%
Initial term of the warrant		5 years
Average exercise price warrants \| € / shares		€ 140.59
Volume of days		30 days